

26th – 28th September 2007

1st European Conference on Schizophrenia Research –

Perspectives from European Networks

Düsseldorf, Germany

Co-Sponsors



WPA World Psychiatric Association
and its Section on Schizophrenia



AEP Association of European
Psychiatrists



DGPPN German Society of
Psychiatry, Psychotherapy
and Nervous Diseases

www.schizophrenianet.eu

FINAL PROGRAMME

TABLE OF CONTENTS

	Page
Welcome Address	1
Conference Organisation	2
Conference Information	3
General Information on Düsseldorf	6
Format Descriptions /CME Credits	7
Opening Ceremony and Welcome Reception	8
Overview Scientific Programme	9
Scientific Programme	
Wednesday, 26 September.....	12
Thursday, 27 September.....	13
Friday, 28 September.....	21
List of Exhibitors and Floorplan	28
Index Chairpersons and Authors	29

Dear Colleagues,

During the last decades considerable progress has been achieved in the treatment of schizophrenia and in the investigation of the etiology and the pathomechanisms of this disorder. However, many questions concerning e.g. the pathogenesis, early recognition as well as optimal treatment regimens still remain unsolved. In order to answer some of the most urgent questions concerted national or European research actions have been initiated during the last years. Even more progress may be achieved if such networking would be more coordinated and concentrated.

Against this background the German Research Network on Schizophrenia organizes for the first time the European Conference on Schizophrenia Research – Perspectives from European Networks to be held from 26 September, 2007 to 28 September 2007 in Düsseldorf, Germany. One focus of this year's conference is on results from network research in particular concerning the prodromal and first-episode stages of schizophrenia. Several symposia will provide the basis for the scientific exchange on these issues. Moreover, a special workshop shall bring together existing networks in order to mutually learn from each other about research strategies, about experiences in transferring research results into practice as well as about unmet needs, and thus may hopefully offer a chance to promote joint European efforts in schizophrenia research.

Though this focus on network research, all interested colleagues regardless whether they participate in a research network or not are most welcome to present their results and to participate in these sessions.

This year's conference is supposed to launch a series of European conferences on schizophrenia research to be organized every two years in the future. Beyond providing a forum for European network research these conferences shall also address the problem of transferring research into practice. Therefore we want to focus on this challenge in upcoming conferences by not only presenting new research data but also by discussing their impact on practice and to explicitly elaborate take home messages for the practice.

We are proud that our scientific concept gained support of the international (WPA), European (AEP), and national (DGPPN) scientific societies, and sincerely hope they will do so as well in future.

On behalf of the scientific committee I would like to cordially welcome you in Düsseldorf.

Sincerely yours



Wolfgang Gaebel
Congress President and Speaker of the German
Research Network on Schizophrenia

Scientific Organisation

German Research Network on Schizophrenia (GRNS)

c/o Rheinische Kliniken Düsseldorf
Prof. Dr. W. Gaebel
PD Dr. W. Wölwer
Dr. V. Toeller
Klinik für Psychiatrie und Psychotherapie der
Heinrich-Heine-Universität Düsseldorf
Bergische Landstraße 2
40629 Düsseldorf, Germany
Phone: +49-211-922-2770
Fax: +49-211-922-2780
Email: [info@kompetenznetz-
schizophrenie.de](mailto:info@kompetenznetz-schizophrenie.de)
www.kompetenznetz-schizophrenie.de

funded by



Federal Ministry
of Education
and Research

The 1st European Conference on Schizo- phrenia is co-sponsored by



WPA World Psychiatric Association
and its Section on Schizophrenia



AEP Association of European
Psychiatrists



DGPPN German Society of
Psychiatry, Psychotherapy
and Nervous Diseases

Local Organisation

PsychoseNetz e.V.
c/o GRNS Head Office, Düsseldorf
German Research Network on Schizophrenia
(GRNS)

Conference and Exhibition Office

CPO **HANSER**[®] SERVICE

CPO HANSER SERVICE
Hanser & Co GmbH
Postfach 12 21
22882 Barsbüttel, Germany
Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
E-Mail: schizophrenia@cpo-hanser.de

Conference Venue

Haus der Ärzteschaft
Tersteegenstraße 9
40474 Düsseldorf, Germany

Scientific Programme Committee

A. G. Awad, Toronto, Canada
H. Beitler, Renningen, Germany
F. Bengtsson, Linköping, Sweden
G. Buchkremer, Tübingen, Germany
H. v. d. Bussche, Hamburg, Germany
P. Falkai, Göttingen, Germany
W. Fleischhacker, Innsbruck, Austria
W. Gaebel, Düsseldorf, Germany
H. Häfner, Mannheim, Germany
C. Höschl, Prague, Czech Republic
R. Holle, Munich, Germany
M. Jorge, Sao Paulo, Brazil
J. Klosterkötter, Cologne, Germany
V. Larach-Walters, Santiago, Chile
W. Maier, Bonn, Germany
M. Maj, Naples, Italy
S. R. Marder, Los Angeles, USA
P. D. McGorry, Melbourne, Australia
J. Mezzich, New York, USA
H.-J. Möller, Munich, Germany
F. Müller-Spahn, Basel, Switzerland
Ch. Raida, Cologne, Germany
W. Rössler, Zurich, Switzerland
P. Ruiz, Huston, USA
G. Schliebener, Herford, Germany
W. Wölwer, Düsseldorf, Germany
M. Wolfersdorf, Bayreuth, Germany

Conference Registration Counter

All conference documentation will be available at the conference registration counter located in the Foyer on the ground floor of the Haus der Ärzteschaft. The conference staff will be pleased to help you with all enquiries regarding registration, conference material and conference programme. Please do not hesitate to contact the staff members if there is anything they can do to make your stay more enjoyable.

Opening hours

Wednesday, 26 September 2007

12.00 pm – 6.30 pm

Thursday, 27 September 2007

8.00 am – 6.30 pm

Friday, 28 September 2007

8.00 am – 4.30 pm

During these opening hours the conference counter can be reached at:

Telephone: +49-151-15 31 90 79

Telefax: +49-211-65 85 26 17

Registration Fee

Payment received after 30 June 2007

EUR 120

Registration fee for participants includes:

- Admission to all scientific sessions during the conference
- Admission to the technical exhibition and poster exhibition
- Conference documentation e.g. final programme and abstract book
- Admission to the Opening Ceremony and Welcome Reception on Wednesday, 26 September 2007
- Coffee breaks from Wednesday, 26 September to Friday, 28 September 2007

On-Site Registration

On-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the number of on-site registered delegates, availability of conference documentation may be limited.

Name Badges

Participants are kindly requested to wear their name badge at all times during the conference.

Certificate of Attendance

A certificate of attendance will be handed out at the registration counter.

Conference Language

The conference language is English. Simultaneous translation will not be provided.

Programme Changes

The organisers cannot assume liability for any changes in the conference programme due to external or unforeseen circumstances.

Technical Exhibition

A technical exhibition will take place in the Foyer on the ground floor of the Haus der Ärzteschaft next to the main lecture hall. For further information please see page 28.

Opening hours

Wednesday, 26 September 2007

2.00 pm – 7.30 pm

Thursday, 27 September 2007

9.00 am – 5.00 pm

Friday, 28 September 2007

9.00 am – 3.00 pm

CONFERENCE INFORMATION

Poster Exhibition

The poster exhibition of the 1st European Conference on Schizophrenia Research is located in the Foyer on the ground floor of the Haus der Ärzteschaft. Posters will be displayed from Thursday, 27 September until Friday, 28 September 2007. They will be sorted by topics and will be numbered within those topics.

The poster exhibition is open to all conference delegates on:

Thursday, 27 September 2007

9.00 am – 7.00 pm

Friday, 28 September 2007

9.00 am – 4.00 pm

The authors of the posters are asked to set up their poster on Wednesday, 26 September 2007, 1.00 pm – 7.00 pm or Thursday, 27 September 2007, 8.30 am – 9.00 am.

Please remove your poster on Friday, 28 September 2007 between 4.00 pm – 5.00 pm. Posters which have not been removed by 5.00 pm will be disposed of by the conference venue.

Abstract Book

All accepted abstracts will be published in an abstract book as a supplement of the European Archives of Psychiatry and Clinical Neurosciences (EAPCN). The abstract book will be handed out together with the conference documentation at the registration counter.

Media Check

The Media Check is located in room 3 on the ground floor of the conference venue close to the registration counter and main lecture hall. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their session but at the latest 90 minutes prior to the presentation.

The presentation will be transferred to a special conference notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook.

Opening hours

Wednesday, 26 September 2007

12.00 pm – 6.30 pm

Thursday, 27 September 2007

8.00 am – 6.30 pm

Friday, 28 September 2007

8.00 am – 3.00 pm

Coffee Breaks

Coffee, tea and mineral water will be served free of charge to all registered delegates during the morning and afternoon coffee breaks from Wednesday, 26 September to Friday, 28 September 2007. Coffee bar stations are located next to the main lecture hall and exhibition area in the Foyer of the Haus der Ärzteschaft.

Lunch and Restaurants

The conference venue provides one restaurant where lunch and snacks will be available on cash basis. Additional restaurants are located nearby the conference venue.

Cloakroom

A cloakroom is available next to the reception in the Foyer on the ground floor of the Haus der Ärzteschaft. Cost per day is EUR 1,50.

Mobile Phones

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

Insurance


The conference fee does not include insurance. All participants are advised to arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of residence.

How to get to the Haus der Ärzteschaft

From central station the conference venue can be reached with the subway line U78 or U79 towards Messe, Duisburg. The stop of the Haus der Ärzteschaft is called Theodor-Heuss-Bücke. Please exit here, walk underneath the bridge and turn right into Tersteegenstrasse. Travel time is approximately 10 minutes.

Parking

Public parking is limited so that participants are recommended to make use of public transportation to reach the conference venue.



GENERAL INFORMATION

City of Düsseldorf

Düsseldorf, the capital of the state of North Rhine-Westphalia, is a posh and modern city with many facets to offer. The local mentality is perfectly reflected in the city's lively cultural and culinary offerings. The city's best-known trademark is the Königsallee ("Kö") with its elegant shopping arcades. Germany's most sophisticated mile is considered one of the world's grand luxurious boulevards.

The Old Town of Düsseldorf is a popular meeting point and entertainment area among locals and visitors. In the picturesque narrow lanes with old churches and bourgeois houses you will find many quaint breweries, ancient pubs, hip bars and clubs. Bordering the Old Town the Rhine river embankment promenade offers a beautiful walk along the Rhine river. People enjoy the views in one of the many bistros and restaurants or board a boat for a trip on the Rhine.

In direct vicinity, there is the Media Harbour, where you can find arts, communication, creativity and spectacular architecture.

Optional Tours

A selection of interesting excursions will invite you to discover the exciting city of Düsseldorf. Tours can be booked on-site at the registration counter at the Haus der Ärzteschaft.

The Brewery Path

Thursday, 27 September 2007

7.00 pm – 9.00 pm

A sociable guided walk through the Old Town will get you acquainted with the most important sights and the history of the "Alt" beer and the home breweries. During the walk, one or several breweries can be visited and beer sampled (to be paid separately on-site).

Price per person: EUR 20,00

The Media Harbour

Thursday, 27 September 2007

7.00 pm – 9.00 pm

Renowned architects such as Frank O. Gehry, David Chipperfield, Joe Coenen, Steven Holl and Claude Vasconi have made the Media Harbour the top address for connoisseurs of architecture from all over the world. Where just a few years ago deserted storage halls emanated an atmosphere of bleakness, internationally renowned companies from the fields of advertising and the arts, communication and TV-production have set up their offices.

Price per person: EUR 20,00



Ulrich Otte - Düsseldorf Marketing & Tourismus GmbH

Symposia

Symposia focus on new developments on diagnosing schizophrenia, on the main research topics of the GRNS as well as on the neurobiological aspects of the early course of schizophrenia and the neuropsychology of this psychiatric disease. All sessions will be given by distinguished and honourable experts in a specific topic of major interest.

Workshop

The workshop is scheduled for 225 minutes, which includes brief presentations by individual panel members followed by contributions from national networks regarding potential joint European research activities. This session type provides for substantial audience participation and should be highly interactive.

Oral Presentations

Oral Presentation sessions are scheduled for 105 minutes and include a maximum of six speakers chaired by a selected specialist. Each speaker has no more than 17 minutes for his/her presentation including time for discussion.

Guided Poster Tours

All accepted poster abstracts will be presented during the conference. Guided poster tours have been arranged in order to give authors the opportunity to present their findings and to discuss them with the audience. These sessions are chaired by recognised experts for the feature topic. The poster exhibition is located in the Foyer on the ground floor of the Haus der Ärzteschaft. Tours are scheduled for **Thursday, 27 September from 2.20 pm – 3.20 pm** and for **Friday, 28 September 2007 from 2.30 pm – 3.30 pm**. Within the poster exhibition the posters are numbered and sorted by topic.

Satellite Symposium

A Satellite Symposium will be organised on Friday, 28 September by Janssen Cilag GmbH and is open to all conference delegates.

CME (Continuing Medical Education) and EACCME Credits

The European Conference on Schizophrenia Research (ECSR) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uments.net.

The ECSR is designated for a maximum of 18 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

The EACCME has granted **18 European CME credits** (ECMEC) to the conference.

The **Nordrheinische Akademie für ärztliche Fort- und Weiterbildung** has granted **19 points** to the conference. The following points are given for each conference day:

26 September: 4 points

27 September: 8 points

28 September: 7 points

These points are recognised by the Psychotherapeutenkammer.

Participants interested in obtaining EACCME credits and CME points of the Nordrheinische Akademie für ärztliche Fort- und Weiterbildung (please provide your bar code) may contact the staff at the CME counter on the last day of attendance in order to receive a printed copy of their accreditation certificate.

Wednesday, 26 September 2007

2.00 pm, Room 1

Welcome Addresses

Prof. W. Gaebel, Düsseldorf, Germany
On behalf of GRNS

Dr. G. Hausdorf, Bonn, Germany
On behalf of the BMBF

Prof. C. Höschl, Prague, Czech Republic
On behalf of the AEP

Prof. V. Larach-Walters, Santiago, Chile
On behalf of the WPA-Section on schizophrenia

Prof. K. D. Pfeffer, Düsseldorf, Germany
On behalf of the Medical Faculty, University Düsseldorf

Prof. F. Müller-Spahn, Basel, Switzerland
On behalf of the GRNS-Advisory Board

Award Ceremony of the Aretaeus-Award Winner 2007

Presidential Symposium

Future perspectives in diagnosing schizophrenia:
Bridging the gap between phenomenology and neurobiology

Welcome Reception

At the end of the Presidential Symposium the participants are invited to join the Welcome Reception in the Foyer of the Haus der Ärzteschaft. Finger food and drinks will be provided.

Time	Room	Room 1	Room 2	Foyer
2.00 pm - 3.10 pm		Opening/Award Ceremony		Registration 12.00 pm - 06.30 pm Technical Exhibition 02.00 pm - 07.30 pm
3.15 pm - 4.30 pm		S-01 Presidential Symposium		
4.30 pm - 4.50 pm	Coffee Break			
4.50 pm - 6.05 pm		S-01 (Continued) Future perspectives in diagnosing schizophrenia: Bridging the gap between phenomenology and neurobiology		
6.15 pm - 7.30 pm	Welcome Reception / Get Together in the Foyer of the Haus der Ärzteschaft			

Abbreviations

S – Symposium

O – Oral Presentation

W – Workshop

P – Guided Poster Tour

SA – Satellite Symposium

Room	Room 1	Room 2	Foyer	
Time				
9.00 am - 10.45 am	S-02 Perspectives in early psychosis: Early recog- nition, early treatment	S-03 Functional and neurobiological disturbances during the early course of schizophrenia		Registration 8.00 am - 6.30 pm
10.45 am - 11.15 pm	Coffee Break			Technical Exhibition 9.00 am - 6.00 pm
11.15 am - 1.00 pm	S-02 Continued	0-01 Neuroimaging and neurophy- siology		
1.00 pm - 2.30 pm	Lunch Break		1.20 pm - 2.20 pm P-01 to P-05	
2.30 pm - 4.15 pm	S-04 Acute and longterm treatment: Treatment of first-episode schizophrenia	0-02 Psychological treatment and rehabilitation		
4.15 pm - 4.45 pm	Coffee Break			
4.45 pm - 6.30 pm	S-04 Continued	S-05 Neuropsy- chology of schizophrenia: Experimental approaches		
6.30 pm - 7.00 pm				

Time	Room	Room 1	Room 2	Foyer
9.00 am - 10.40 am		W-01 Network research in schizophrenia – a European perspective?	O-03 Genetic research	Registration 8.00 am - 4.30 pm Technical Exhibition 9.00 am - 3.00 pm
10.40 am - 11.00 pm	Coffee Break			
11.00 am - 12.45 pm	W-01 Continued	O-04 Course of schizophrenia and new strategies of care		
12.45 pm - 1.15 pm	Closing Ceremony			
1.15pm - 2.45 pm	Lunch Break		1.30 pm - 2.30 pm P-06 to P-09	
2.45 pm - 4.30 pm	SA-01 Prevention of functional disturbances: How to accomplish?	O-05 Prodromal stage of schizophrenia		
4.30 pm - 4.45 pm				

OPENING CEREMONY

2.00 pm – 3.00 pm Room 1

W. Gaebel, Düsseldorf, Germany

On behalf of GRNS

G. Hausdorf, Bonn, Germany

On behalf of the BMBF

C. Höschl, Prague, Czech Republic

On behalf of the AEP

V. Larach-Walters, Santiago, Chile

On behalf of the WPA-Section on schizophrenia

K.D. Pfeffer, Düsseldorf, Germany

On behalf of the Medical Faculty, University Düsseldorf

F. Müller-Spahn, Basel, Switzerland

On behalf of the GRNS-Advisory Board

AWARD CEREMONY

3.00 pm – 3.10 pm Room 1

Awards ceremony of the Aretaeus-Award Winner 2007

S-01 PRESIDENTIAL SYMPOSIUM

3.15 pm – 6.05 pm Room 1

Future perspectives in diagnosing schizophrenia: Bridging the gap between phenomenology and neurobiology

Chairs: C. Höschl, Prague, Czech Republic
F. Müller-Spahn, Basel, Switzerland

S-01-01

Problems associated with the current classification and diagnosis of schizophrenia

H.-J. Möller, Munich, Germany

S-01-02

The future role of cognition in the diagnosis of schizophrenia – towards DSM-V

R. Keefe, Durham, North Carolina, USA

S-01-03

Neural mechanisms of genetic risk for schizophrenia

A. Meyer-Lindenberg, Bethesda, Maryland, USA/Mannheim, Germany

S-01-04

The future contribution of genetics to the diagnosis of schizophrenia

W. Maier, Bonn, Germany

S-01-05

Functional psychopathology: A future framework for diagnosing schizophrenia

W. Gaebel, Düsseldorf, Germany

S-01-06

Diagnosing schizophrenia – stigmatization included?

W. Rössler, Zurich, Switzerland

S-02 SYMPOSIUM

9.00 am – 1.00 pm

Room 1

Perspectives in early psychosis: Early recognition, early treatment

Chairs: J. Klosterkötter, Cologne, Germany
S. Lewis, Manchester, United Kingdom

S-02-01

Early recognition, early treatment: State of the art

S. Lewis, Manchester, United Kingdom

S-02-02

Development and evaluation of an early recognition inventory

H. Häfner, K. Maurer, Mannheim, Germany

S-02-03

The contribution of neurobiology to early recognition

M. Wagner, W. Maier, Bonn, Germany

S-02-04

Biomarker profiles in prodromal and first onset stages of schizophrenia

M. Leweke, Cologne, Germany
S. Bahn, Cambridge, United Kingdom

S-02-05

Psychological and pharmacological interventions for persons at risk of psychosis

S. Ruhrmann, A. Bechdorf, Cologne, Germany

S-02-06

The European prediction of psychosis study (EPOS) – design, recruitment and first results

R. K. R. Salokangas, Turku, Finland

Discussion

Discussant: M. Marshall, Manchester, United Kingdom

S-03 SYMPOSIUM

9.00 am – 10.45 am

Room 2

Functional and neurobiological disturbances during the early course of schizophrenia: Treatment and relation to outcome

organised by the WPA Section on Schizophrenia

Chairs: H. Lublin, Glostrup, Denmark
B. Glenthoj, Glostrup, Denmark

S-03-01

The association between premorbid functioning, duration of untreated psychosis and outcome among patients with first-episode schizophrenia spectrum psychosis

M. Nordentoft, Copenhagen, Denmark

S-03-02

Dopamine D2 receptors binding potentials in neuroleptic-naïve first-episode schizophrenic patients: Relation to treatment outcome

B. Glenthoj, Glostrup, Denmark

S-03-03

Brain imaging in first-episode schizophrenia

A. Vita, Brescia, Italy

S-03-04

The neurotoxicity of psychosis: A five-year longitudinal MRI study in first-episode schizophrenia

W. Cahn, Utrecht, The Netherlands

S-03-05

Mechanisms underlying hippocampal pathology in schizophrenia: Failure in synaptogenesis, neurogenesis or both?

P. Falkai, Göttingen, Germany

O-01 ORAL PRESENTATION

11.15 am – 1.00 pm

Room 2

Neuroimaging and neurophysiology

Chairs: A. Vita, Brescia, Italy
G. Winterer, Düsseldorf, Germany

O-01-01

Using neuroimaging to characterize patients with psychoses according to brain morphological, physiological and functional parameters

O. Gruber, Göttingen, Germany

O-01-02

Duration of illness and working memory in schizophrenia: An fMRI investigation

V. Kumari, London, United Kingdom
S. Elsabagh, P. Premkumar, A. Anilkumar

O-01-03

Functional cerebral indicators of relapse: Results from the German research network on schizophrenia

M. Reske, Aachen, Germany
U. Habel, T. Kellermann, T. Stöcker, N. J. Shah, K. Zilles, D. F. Braus, A. Schmitt, R. Schlösser, M. Wagner, I. Frommann, T. Kircher, A. Rapp, E. Meisenzahl, S. Ufer, S. Ruhrmann, R. Thienel, H. Sauer, F. A. Henn, W. Gaebel, F. Schneider

O-01-04

Neuronal synchrony as a pathophysiological mechanism in schizophrenia

P. Uhlhaas, Frankfurt, Germany
E. Rodriguez, F. Roux, C. Haenschel, K. Maurer, W. Singer

O-01-05

Latency classification of the frontal MMN responses in schizophrenia

J. Zislin, Jerusalem, Israel
V. Rodionov, R. Durst, M. Mager, A. Teitelbaum, S. Raskin, M. Shlafman

O-01-06

„Mismatch negativity“ in the visual modality is reduced among patients with schizophrenia

J. Libiger, Hradec Kralove, Czech Republic
A. Urban, J. Kremlacek, M. Kuba

P-01 GUIDED POSTER TOUR

1.20 pm – 2.20 pm

Foyer

Prodromal Stage I

Chair: R. K. R. Salokangas, Turku, Finland

P-01-01

Development and implementation of an early detection and intervention programme for persons at-risk for psychosis

F. Schultze-Lutter, Cologne, Germany
J. Klosterkötter, W. Maier, H. Häfner, S. Ruhrmann, A. Bechdorf, M. Wagner, K. Maurer

P-01-02

Who initiates first help-seeking? Results from a retrospective study of first-episode psychosis

A. Niedersteberg, Duisburg, Germany
F. Schultze-Lutter, S. Ruhrmann, V. Veith, J. Klosterkötter

P-01-03

Pathways to psychosis: A comparison of the pervasive developmental disorder subtype multiple complex developmental disorder and the “At Risk Mental State”

M. Sprong, Utrecht, The Netherlands
P. Schothorst, H. Swaab, H. van Engeland

P-01-04

Vulnerability to psychosis delays recovery from of depression – results of the RADEP study

R. K. R. Salokangas, Turku, Finland
S. Luutonen

P-01-05

Increased abnormal involuntary movements in "at high risk of developing psychosis group" a comparative study

V. Sanchez, Barcelona, Spain

M. R. Broome, L. R. Valmaggia, P. Dazzan, P. McGuire

P-01-06

Emotion recognition in ultra-high risk individuals and the risk of early transition to psychosis

M. Schloegelhofer, Vienna, Austria

M. Schaefer, K. Papageorgiou

P-01-07

Is the ER1raos checklist a scale of psychosis proneness? Applying the RASCH model on checklist data

K. Maurer, Mannheim, Germany

G. Trendler, F. Hörmann, H. Häfner

P-01-08

Psychometric properties of the "Schizophrenia Proneness Instrument, Adult Version" (SPI-A)

H. Picker, Cologne, Germany

F. Schultze-Lutter, S. Ruhrmann

P-01-09

Alcohol and drug consumption: Prevalence and effect on the transition to psychosis

F. Rausch, Mannheim, Germany

K. Maurer, F. Hörmann, H. Häfner

P-01-10

Impact of locus of control on cannabis abstinence

M. Neumann, Cologne, Germany

S. Ruhrmann, F. Schultze-Lutter

P-02 GUIDED POSTER TOUR

1.20 pm – 2.20 pm

Foyer

Treatment I

Chair: W. Fleischhacker, Innsbruck, Austria

P-02-01

Invalidity family communication patterns in schizophrenia families

F. Bahrami, Isfahan, Iran

A. Zamani, N. Kassaiean

P-02-02

Multifamily intervention – a new approach in the treatment of schizophrenia

H. Berger, Riedstadt, Germany

P-02-03

Prismatic communication

A. Drees, Krefeld, Germany

P-02-04

Training of Affect Recognition (TAR) in schizophrenia: Generalizability and durability of training effects

N. Frommann, Düsseldorf, Germany

J. Fleiter, M. Peltzer, A. Steinbring, W. Wölwer

P-02-05

Affect recognition and violence in schizophrenia: Application of the Training of Affect Recognition (TAR) in forensic patients

N. Frommann, Düsseldorf, Germany

M. Brand, W. Schmidbauer, W. Wölwer

P-02-06

Illness concepts, insight into illness and compliance in schizophrenic patients: Their interrelation and meaning for the effectiveness of psychoeducative treatment interventions

F. Schmidt, Berlin, Germany
K. Körtner, M. Dettling

P-02-09

Implication of the vascular factor in treatment resistance to patients with schizophrenia treated with antipsychotics

D. G. C. Marinescu, Craiova, Romania
T. Udristoiu, D. Camen, A. Tiugan,
A. Chimorghiacis, C. Radut

P-02-10

Switching from branded to generic risperidone in patients with schizophrenia: An estimation of potential economic consequences in the Netherlands

M. van Agthoven, Tilburg, The Netherlands
F. van Nooten, C. Rijnders, R. Brown

P-02-11

Treatment of schizophrenia in breast cancer patients

V. Sushko, Odessa, Ukraine

P-03-02

Association between reelin and schizophrenia and the influence of reelin on volumetric changes

I. Puls, Berlin, Germany
F. Schlagenhaut, C. Liensdorf, J. Wrase,
J. Gallinat, A. Heinz

P-03-03

Decreased oligodendrocyte number in the hippocampus of schizophrenia patients – a stereological study

P. Falkai, Göttingen, Germany
A. Schmitt, C. Steyskal, H.-G. Bernstein,
B. Bogerts

P-03-04

Relationship between Kynurenines and S100b in CSF of schizophrenic patients

M. J. Schwarz, München, Germany
M. Riedel, S. Holdenrieder, M. Tischinger,
N. Müller

P-03-05

White matter abnormalities in subjects with ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls

H. Witthaus, Bochum, Germany
M. Brüne, C. Kaufmann, G. Bohner, S. Özgürdal,
Y. Gudlowski, A. Heinz, R. Klingebiel, G. Juckel

P-03-06

Gray matter abnormalities in subjects with ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls

H. Witthaus, Bochum, Germany
C. Kaufmann, G. Bohner, S. Özgürdal,
Y. Gudlowski, J. Gallinat, M. Brüne, A. Heinz,
R. Klingebiel, G. Juckel

P-03-07

Reduced temporal and prefrontal cortical thickness in adolescents with early-onset schizophrenia

A. Lamprecht, Frankfurt, Germany
R. Bittner, A. Rotarska-Jagiela, F. Härtling,
W. Singer, K. Maurer, R. Goebel, D. Linden,
C. Haenschel

P-03 GUIDED POSTER TOUR

1.20 pm – 2.20 pm

Foyer

Neurobiology

Chair: P. Falkai, Göttingen, Germany

P-03-01

A case control study: No association between SLC6A3 (DAT1) with schizophrenia

H. Galehdari, Ahwaz, Iran
A. M. Foroughmand

P-03-09

The place of neurotropic staffs in the correction of antioxydantic functions of different departments of brain

T. Skachko-Volkova, Dnepropetrovsk, Ukraine
H. Zlenko, Y. Khomenko

P-03-10

B-lymphoblasts as an in vitro cell model for the study of nicotinic acetylcholine receptor regulation in schizophrenics in relation to nicotine abuse

S. Ferrea, Düsseldorf, Germany
U. Henning, C. Luckhaus

P-03-11

Elevated glutamate in the hippocampus and reduced glutamate in the anterior cingulate gyrus of schizophrenic patients – a 1H-MRS study at 3 tesla

K. Leopold, Dresden, Germany
M. Krebs, I. Häke, F. Schubert, F. Seifert, M. Schäfer, J. Gallinat

P-04-03

Visual working memory deficits in adolescents with early-onset schizophrenia investigated with event-related functional magnetic resonance imaging

R. Bittner, Frankfurt, Germany
C. Haenschel, A. Roebroek, F. Härtling, A. Rotarska-Jagiela, R. Goebel, W. Singer, K. Maurer, D. Linden

P-04-04

Neuronal correlates of emotion recognition in schizophrenia

D. Mier, Giessen, Germany
S. Lis, C. Sauer, K. Zygodnik, C. Esslinger, B. Gallhofer, P. Kirsch

P-04-05

Hypoactivity bilateral in Wernicke's area in schizophrenia patients and their unaffected family members

V. Oertel, Frankfurt, Germany
A. Rotarska-Jagiela, M. Lindner, C. Altmann, C. Knöchel, V. van de Ven, C. Haenschel, K. Maurer, D. Linden

P-04 GUIDED POSTER TOUR

1.20 pm – 2.20 pm

Foyer

Neurocognition / Neurofunction

Chair: O. Gruber, Göttingen, Germany

P-04-06

Impaired early-stage visual processing contributes to working memory dysfunction in adolescents with schizophrenia

C. Haenschel, Frankfurt, Germany
R. Bittner, F. Härtling, A. Rotarska-Jagiela, K. Maurer, W. Singer, D. Linden

P-04-01

Reduced cortical inhibition in schizophrenia

T. Wobrock, Göttingen, Germany
M. Schneider, D. Kadovic, P. Falkai

P-04-02

Brain reward system activation and the relationship between motivation and emotion in schizophrenia

P. Kirsch, Giessen, Mannheim, Germany
D. Mier, S. Ronshausen

P-04-07

Saccadic distractibility, as shown by the antisaccade task, is associated with genetic loading for schizophrenia

N. Petrovsky, Bonn, Germany
F. Weiss-Motz, I. Frommann, S. Schulze-Rauschenbach, C. Weiler, E. Matuschek, A. Brockhaus-Dumke, J. Dreher, S. Ruhrmann, M. Wagner

P-04-08

Neurocognitive deficits in first episode schizophrenia patients and their siblings

I. V. Miclutia, Cluj-Napoca, Romania
C. A. Popescu, R. Macrea, I. Craciun

P-05 GUIDED POSTER TOUR

1.20 pm – 2.20 pm

Foyer

Miscellaneous

Chair: W. Rössler, Zurich, Switzerland

P-05-01

Incidence of schizophrenia is not declining

R. K. R. Salokangas, Turku, Finland
A.-M. Koivisto, H. Rantanen, H. Oja,
M. Joukamaa

P-05-02

Psychopathology of schizophrenia: A Riemann' Turn Ahead ?

N. Andersch, London, United Kingdom

P-05-03

Treatment of schizophrenia in somatic inpatients of general hospital

V. Prokudin, Moscow, Russia
Y. Boyko

P-05-05

Reduction of stigma and discrimination because of schizophrenia – the antistigma – project of the GRNS

A. Baumann, Düsseldorf, Germany
H. Zäske, W. Gaebel

P-05-06

Relationship between insight in schizophrenia and psychosocial variables in community clinical case management

S. Caton, Berlin, Germany
W. Kaiser

P-05-07

Public attitudes towards people with a mental illness before and two years after the opening of a psychiatric day hospital and outpatient department

H. Zäske, Düsseldorf, Germany
A. Baumann, W. Gaebel

P-05-08

Relationship between quality of life, psychopathological symptoms, substance consumption and adherence to treatment in patients with schizophrenia

I. Vanelli, Novara, Italy
S. Pombo, E. Torre, P. Levy

P-05-09

Study of basic symptoms in schizophrenia patients in north west of Iran

P. Molavi, Ardebil, Iran
H. Ghamarigivi, E. Rezaei Ghalechi, S. Saeedlou,
R. Arab, S. Arshi

P-05-10

Insomnia and its role in schizophrenia

P. Bosch, Venlo, The Netherlands
M. van den Noort

P-05-11

Investigative report from personal data of schizophrenic patient in Shiraz psychiatric centers Iran

Y. Kalafi, Shiraz, Iran

S-04 SYMPOSIUM

2.30 pm – 7.00 pm

Room 1

Acute and long-term treatment: Treatment of first-episode schizophrenia

Chairs: F. Müller-Spahn, Basel, Switzerland
W. Gaebel, Düsseldorf, Germany

S-04-01

Treatment of first-episode schizophrenia: State of the art

R. Emsley, Cape Town, South Africa

S-04-02

Optimization of acute treatment in first-episode schizophrenia patients by new pharmacological treatments

H.-J. Möller, Munich, Germany

S-04-03

Pharmacological long-term treatment strategies in first-episode schizophrenia: Are there advantages of new atypical antipsychotics compared to low-dose first generation antipsychotics?

W. Gaebel, Düsseldorf, Germany

S-04-04

Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens (EUFEST)

W. Fleischhacker, Innsbruck, Austria

S-04-05

The MESIFOS trial; guided discontinuation versus maintenance treatment in remitted first episode psychosis: Relapse rates and functional outcome

L. Wunderink, Groningen, The Netherlands

S-04-06

Psychological interventions in first-episode schizophrenia patients

S. Klingberg, Tübingen, Germany

S-04-07

The Danish National Schizophrenia project (DNS): A large scale prospective investigation of aspects of psychodynamic and integrated treatment

B. Rosenbaum, Glostrup, Denmark

S-04-08

Roundtable: Conclusions from recent treatment studies in first-episode schizophrenia

Chair: S. Marder, Los Angeles, USA

S. Lewis, Manchester, United Kingdom

M. Nordentoft, Copenhagen, Denmark

L. Wunderink, Groningen, The Netherlands

B. Rosenbaum, Glostrup, Denmark

R. Emsley, Cape Town, South Africa

W. Gaebel, Düsseldorf, Germany

H.-J. Möller, Munich, Germany

S. Klingberg, Tübingen, Germany

O-02 ORAL PRESENTATION

2.30 pm – 4.15 pm

Room 2

Psychological treatment and rehabilitation

Chairs: W. Wölwer, Düsseldorf, Germany
V. Larach-Walters, Santiago, Chile

O-02-01

The need of integral assessment and management in the treatment plan of schizophrenia: Rehabilitation needs unmet

V. Larach-Walters, Santiago, Chile

O-02-02

A randomised controlled multi-centre study of Integrated Neurocognitive Therapy (INT) for schizophrenia patients

M. Lächler, Bern, Switzerland

D. R. Müller, V. Roder

O-02-03

Psychological interventions for cognitive and emotional dysfunctions in schizophrenia – results from the German Research Network on Schizophrenia

W. Wölwer, Düsseldorf, Germany

N. Frommann, M. M. Dreher-Rudolf, A. Piaszek,

S. Halfmann, M. Streit, R. Vauth

O-02-04

Remediation of neurocognition and social cognition in schizophrenia: Empirical evidence supporting combined treatment approaches

D. R. Müller, Bern, Switzerland

M. Lächler, V. Roder

O-02-05

Psychoeducation in schizophrenia: Does a preceding cognitive training enhance therapeutic effects?

G. Pitschel-Walz, Munich, Germany
J. Bäuml, S. Kraemer, T. Froböse, A. Gsottschneider, C. Pohl, T. Jahn

O-02-06

Evaluation of 2 years' residential care treatment for adolescents and young adults with schizophrenia

M. Hemmerle, Essen, Germany
B. Röpcke, C. Eggers, R. D. Oades

S-05 SYMPOSIUM

4.45 pm - 6.30 pm

Room 2

Neuropsychology of schizophrenia: Experimental approaches

Chairs: B. Gallhofer, Giessen, Germany
P. Kirsch, Giessen, Mannheim, Germany

S-05-01

Uncontrollable voices and their relationship to gating deficit in schizophrenia

V. Kumari, London, United Kingdom

S-05-02

Backward masking: A potential endophenotype for schizophrenia

A. Brand, Bremen, Germany

S-05-03

Genetic and neuroimaging studies of oculomotor endophenotypes

U. Ettinger, London, United Kingdom

S-05-04

Sensory and motor encoding strategies in N-back tasks: Implications for working memory deficits in schizophrenia

S. Lis, Giessen, Germany

S-05-05

Abnormal functional and structural connectivity in schizophrenia - experimental approaches and neurogenetic results

A. Meyer-Lindenberg, Bethesda, Maryland, USA/ Mannheim, Germany

S-05-06

Adaptive tasks: An experimental approach to deal with the performance-activation problem in neuroimaging studies

P. Kirsch, Giessen, Mannheim, Germany

W-01 WORKSHOP

9.00 am – 12.45 pm

Room 1

Network research in schizophrenia – a European perspective?

Chairs: W. Gaebel, Düsseldorf, Germany
C. Höschl, Prague, Czech Republic

W-01-01

Introduction

W. Gaebel, Düsseldorf, Germany
Speaker of the German Research Network on Schizophrenia

W-01-02

Trends in schizophrenia research from the European perspective

C. Höschl, Prague, Czech Republic
President of the Association of European Psychiatrists AEP

W-01-03

Health research in the 7th research framework programme of the EU

A. Cesario, Brussels, Belgium
European Commission – Medical and Public Health Research
D. Dollase, Brussels, Belgium
EU Liaison Office of German Research Organisations (KoWi)

Contributions from national networks regarding potential joint European research activities

W-01-04

A Joint E-based Database for Sensitive Data (SeGrid)

M. Nordentoft, Copenhagen, Denmark

W-01-05

Brain-Net Europe/Molecular Etiology of Schizophrenia (MEOS)

P. Falkai, Göttingen, Germany

W-01-06

Genetic Risk and Outcome of Psychosis (GROUP) Network/Rob Giel Research Center

L. Wunderink, Groningen, The Netherlands

W-01-07

German Research Network on Schizophrenia (GRNS)

W. Wölwer, Düsseldorf, Germany

W-01-08

Mental Health Research Network (MHRN)/PsyGrid

S. Lewis, Manchester, United Kingdom
T. Wykes, London, United Kingdom

W-01-09

First Episode Research Network (FERN)

K. Fahy, Sheffield, United Kingdom

W-01-10

European Prediction of Psychosis Study (EPOS)

J. Klosterkötter, Cologne, Germany

W-01-11

Swiss Early Psychosis Project (SWEPP)

A. Simon, Bruderholz, Switzerland

Discussion

O-03 ORAL PRESENTATION

9.00 am – 10.40 am

Room 2

Genetic research

Chairs: W. Maier, Bonn, Germany
F. Bengtsson, Linköping, Sweden

O-03-01

A complementary strategy to approach the genetics of schizophrenia

D. Rujescu, Munich, Germany

O-03-02

The role of NRG1 in genetics of schizophrenia in Iranian population

M. Behmanesh, Tehran, Iran
S. A. Mohamad Shariati, A. Fathian, H. Glaehdari

O-03-03

Influence of the COMT Val158Met Polymorphism in the clinical outcome in schizophrenia

F. Ortuno, Pamplona, Spain
P. Molero, P. Lopez-Garcia, A. Patino-Garcia

O-03-04

Evaluating the role of epigenetic factors in psychiatric disorders

P. J. Rogue, Strasbourg, France

O-03-05

The influence of dysbindin (DTNBP1) gene variants on negative symptoms and prefrontal activation during working memory performance in schizophrenic patients

I. Puls, Berlin, Germany
F. Schlagenhauf, D. Müller, S. Büttner, J. Wrase, J. Gallinat, A. Heinz

O-03-06

A model of schizophrenia

T. Schelde, Frederiksberg, Denmark

O-03-07

Response prediction of antipsychotic therapy – results from the KNS study

R. Mössner, Bonn, Germany

O-04 ORAL PRESENTATION

11.00 am – 12.45 pm

Room 2

Course of schizophrenia and new strategies of care

Chairs: G. Awad, Toronto, Canada
J. Libiger, Hradec Kralove, Czech Republic

O-04-01

Longitudinal analyses of psychotic experiences in the Zurich Study

W. Rössler, Zurich, Switzerland
V. Ajdacic-Gross, A. Gamma, K. Landolt, N. Stulz, J. Angst

O-04-02

Beyond the critical period: A longitudinal study of outcome in the eight years after a first episode of psychosis

N. Crumlish, Dublin, Ireland
P. Whitty, M. Clarke, S. Browne, M. Kamali, M. Gervin, O. McTigue, A. Kinsella, J. L. Waddington, C. Larkin, E. O'Callaghan

O-04-03

Schizophrenia – neuropsychological aspects of suicidal behaviour

D. Cosman, Cluj-Napoca, Romania
M. Manea, S. Nica, B. Nemes, H. Coman

O-04-04

Improving outpatient treatment in schizophrenia: Effects of computerized guideline implementation – results of a multicenter-study within the German Research Network on Schizophrenia

B. Janssen, Düsseldorf, Germany

O-04-05

Enforcing antipsychotic treatment in the community setting – does it work?

S. Lanquillon, Busselton, Australia
D. Fischer-Barnicol

O-04-06

Health promotion in mental health settings – a European network of mental health services

H. Berger, Riedstadt, Germany

CLOSING CEREMONY

12.45 pm – 1.15 pm

Room 1

Perspectives of the ECSR

P-06 GUIDED POSTER TOUR

1.30 pm – 2.30 pm

Foyer

Prodromal Stage II

Chair: S. Ruhrmann, Cologne, Germany

P-06-01

Softly, softly catchee monkey – starting an early detection service for persons at risk of psychosis

F. Schultze-Lutter, Cologne, Germany
S. Ruhrmann, J. Klosterkötter

P-06-02

Basic symptoms in the prediction of psychosis

F. Schultze-Lutter, Cologne, Germany
S. Ruhrmann, H. Picker, J. Klosterkötter

P-06-03

Social and academic premorbid adjustment in first psychotic episode

A. Barajas Velez, Barcelona, Spain
I. Banos Yeste, S. Ochoa Güerre, J. Usall Rodie, V. Villalta Gil, A. Fargas Villanueva, M. Dolz Abadia, B. Sanchez Fernandez, J. A. Alda Diez, J. M. Haro Abad

P-06-04

Patterns of depression in subjects at high risk for psychosis

H. Graf von Reventlow, Cologne, Germany
S. Ruhrmann, F. Schultze-Lutter, M. Heinimaa, P. Patterson, P. Dingemans, G. Juckel, D. Linszen, R. K. R. Salokangas, M. Birchwood, J. Klosterkötter

P-06-05

Assessment of self-reported early trauma as a risk factor for psychosis with the Trauma and Distress Scale (TADS)

H. Graf von Reventlow, Cologne, Germany
R. K. R. Salokangas, P. Patterson, S. Luutonen, J. Huttunen, M. Heinimaa, M. Birchwood, D. Linszen, G. Juckel, S. Ruhrmann, J. Klosterkötter

P-06-06

Life events and the initial prodrome of schizophrenia

H. Picker, Cologne, Germany
F. Schultze-Lutter, S. Ruhrmann

P-06-07

Competence and control orientation in putatively prodromal persons

S. Ruhrmann, Cologne, Germany
J. Paruch, F. Schultze-Lutter, H. Picker, H. Graf von Reventlow, M. Neumann, V. Veith, A. Bechdolf, J. Klosterkötter

P-06-08

Subjective quality of life in initial prodromal states of psychosis and its possible determinants – results from the German Research Network on Schizophrenia

S. Ruhrmann, Cologne, Germany
J. Paruch, A. Bechdolf, M. Wagner, H.-J. Möller, W. Gaebel, W. Maier, J. Klosterkötter

P-06-09

Schizotypal features and risk of psychosis – results of the EPOS group

R. K. R. Salokangas, Turku, Finland
M. Heinimaa, J. Klosterkötter, S. Ruhrmann, H. Graf von Reventlow, D. Linszen, P. Dingemans, M. Birchwood, P. Patterson

P-06-10

Prodromal symptoms prior to a first episode in schizophrenia and prior to a relapse: Comparison of prevalence and predictive validity

M. Riesbeck, Düsseldorf, Germany
K. Maurer, H. Häfner, W. Gaebel

P-07 GUIDED POSTER TOUR

1.30 pm – 2.30 pm

Foyer

Treatment II

Chair: H.-J. Möller, Munich, Germany

P-07-02

Generic substitution of an atypical brand antipsychotic by a pharmacist will have a negative impact on patients with psychoses/schizophrenia

E. van Gent, Doetinchem, The Netherlands

B. Roman

P-07-03

Weight management by modular group interventions. Outcome at 24 months in an Irish cohort with severe mental illness (SMI)

C. Bushe, Basingstoke, United Kingdom

C. Haley, D. McNamara, P. Devitt, M. Fleming

McCrossan

P-07-04

The effect of a weight management programme to prevent increasing visceral body fat during treatment with olanzapine

M. Mittrach, Düsseldorf, Germany

J. Thünker, A. Klimke, H. Hauner, J. Cordes

P-07-05

Long-term topiramate treatment in psychotropic drug induced weight gain: A retrospective chart review

Y. Khazaal, Geneva, Switzerland

P-07-06

Cognitive behavioral therapy for obesity and binge eating disorder associated to antipsychotic drugs

Y. Khazaal, Geneva, Switzerland

E. Fresard, A. Chatton, D. Zullino

P-07-07

Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine

F. Schlagenhauf, Berlin, Germany

G. Juckel, M. Koslowski, T. Kahnt, T. Dembler,

B. Knutson, T. Kienast, J. Gallinat, J. Wrase,

A. Heinz

P-07-08

Working memory function and prefrontal cortex activation in schizophrenic patients switched from conventional antipsychotics to the atypical neuroleptic olanzapine

F. Schlagenhauf, Berlin, Germany

T. Wüstenberg, K. Schmack, M. Dinges, J. Wrase,

M. Koslowski, M. Bauer, J. Gallinat, G. Juckel,

A. Heinz

P-07-09

Clozapine induces preadipocyte differentiation

K. Fehsel, Düsseldorf, Germany

C. Luckhaus

P-07-10

Tranquilizing activity of the norbornene row amides

L. Kasyan, Dnepropetrovsk, Ukraine

V. Mamchur, H. Zlenko, T. Skachko, V. Palchikov,

I. Tarabara

P-08 GUIDED POSTER TOUR

1.30 pm – 2.30 pm

Foyer

Neurocognition

Chair: M. Wagner, Bonn, Germany

P-08-01

Theory of mind in schizophrenia: The role of clinical symptomatology in understanding other people's thoughts and intentions

M. Abdel-Hamid, Bochum, Germany

P-08-02

The sense of agency in schizophrenia: Disturbances in predicting action-effect relations can explain abnormalities in action awareness

M. Voss, Berlin, Germany
J. Moore, M. Hauser, D. Kunz, J. Gallinat, A. Heinz, P. Haggard

P-08-03

Poor premorbid adjustment and dysfunctional visual abilities predict theory of mind deficits in chronic stabilized schizophrenic outpatients

R. Duno, Sabedell, Barcelona, Spain
E. Pousa, K. Langohr, A. Tobena

P-08-04

Structural-dynamic features of cognitive functions in an estimation of efficacy of treatment of schizophrenia

N. Govorin, Chata, Russia
A. Panina

P-08-05

Emotional and cognitive functioning in stable schizophrenic patients

M. Jarema, Warszawa, Poland
D. Kukulska, D. Parnowska

P-08-06

Learning potential on the WCST in first-episode and chronic schizophrenia

A. Pedersen, Münster, Germany
K. Koelkebeck, A. Siegmund, T. Suslow, K. H. Wiedl, V. Arolt, P. Ohrmann

P-08-07

Are basic symptoms in schizophrenia associated with working memory deficits? One cross-sectional study in acute patients

M. L. Vargas, Zamora, Spain
N. Jimeno Bulnes

P-08-08

Investigation of variables affecting Theory of Mind (ToM) abilities in a sample of schizophrenia patients

K. Koelkebeck, Münster, Germany
A. Pedersen, P. Ohrmann

P-08-09

The tolerability of rTMS treatment in schizophrenia with respect to cognitive function

M. Mitrach, Düsseldorf, Germany
M. Arends, J. Thünker, G. Kotrotsios, A. Mobascher, T. Wobrock, M. W. Agelink, W. Gaebel, J. Cordes

P-08-10

Neuropsychological and neurophysiological predictors of clinical course in first episode schizophrenia - results from the German Research Network on Schizophrenia

W. Wölwer, Düsseldorf, Germany
W. Gaebel, German Study Group on First Episode Schizophrenia

P-08-11

The dreaming brain as a model for psychosis: An experimental approach using bizarreness as a cognitive marker

I. Limosani, Milan, Italy
A. d' Agostino, M. L. Manzone, S. Scarone

P-09 GUIDED POSTER TOUR

1.30 pm – 2.30 pm

Foyer

Electrophysiology

Chair: J. Libiger, Hradec Kralove, Czech Republic

P-09-01

A new method of single trial analysis of the evoked responses in healthy subjects and schizophrenic patients

J. Zislis, Jerusalem, Israel
V. Rodionov, R. Durst, M. Mager, A. Teitelbaum, S. Raskin, M. Shlafman

P-09-02

Anomalies of auditory oddball ERP in the first episode patients

I. Lebedeva, Moscow, Russia
V. Kaleda, A. Barkhatova, M. Omelchenko

P-09-03

Correlations between mismatch negativity (MMN) and insight in schizophrenia

A. Boxus, Limoux, France

P-09-04

A topographic event-related potential follow-up study in first episode patients with schizophrenia

J. Brinkmeyer, Düsseldorf, Germany

W. Gaebel, German Study Group on First Episode Schizophrenia

P-09-05

Cortical potentials with antisaccades in first-episode schizophrenia

J. Brinkmeyer, Düsseldorf, Germany

W. Gaebel, German Study Group on First Episode Schizophrenia

P-09-06

Prolonged antisaccade latency in individuals clinically at risk for psychosis

I. Frommann, Bonn, Germany

S. Ruhrmann, J. Brinkmeyer, A. Hochrein, A. Brockhaus-Dumke, W. Wölwer, J. Berning, A. Bechdorf, J. Klosterkötter, W. Maier, M. Wagner

P-09-07

Differentially altered auditory P300 topography in individuals clinically at risk for psychosis

I. Frommann, Bonn, Germany

J. Brinkmeyer, S. Ruhrmann, E. Hack, A. Brockhaus-Dumke, A. Bechdorf, W. Wölwer, J. Klosterkötter, W. Maier, M. Wagner

P-09-08

Relationship between P50 Suppression and the Cortical Silent Period

B. Moeller, Stralsund, Germany

J. S. Snyder, H. J. Freyberger, Z. J. Daskalakis

P-09-09

EEG dynamics in visuo-motor integration of schizophrenic patients

S. R. Soekadar, Tübingen, Germany

C. Braun, A. Rilk, C. Arfeller, P. Bremme, C. Plewnia

SA-01 SATELLITE SYMPOSIUM

2.45 pm – 4.45 pm

Room 1

Prevention of functional disturbances: How to accomplish?

supported by an unrestricted educational grant of Janssen-Cilag GmbH

Chair: J. Klosterkötter, Cologne, Germany

SA-01-01

Specific problems and issues in the treatment of first episode schizophrenia patients with focus on functional disturbances

B.G. Schimmelmann, Hamburg, Germany

SA-01-02

Detection of functional disturbances: Clinical and neurobiological aspects

M. Lautenschlager, Berlin, Germany

SA-01-03

Importance of functional disturbances in younger patients with background of migration

H.-J. Assion, Bochum, Germany

SA-01-04

Pharmacological treatment options to reach recovery in first episode patients

P. Falkai, Göttingen, Germany

O-05 ORAL PRESENTATION

2.45 pm – 4.30 pm

Room 2

Prodromal stage of schizophrenia

Chairs: H. Häfner, Mannheim, Germany

M. Marshall, Manchester, United Kingdom

Kingdom

O-05-01

Premorbid schizoid-schizotypal traits and early onset schizophrenia course

M. Kotlicka-Antczak, Lodz, Poland

J. Rabe-Jablonska

0-05-02

Symptoms of the early course influencing the time until transition to psychosis. Applying the Cox model on data of the ERIRAOS symptomlist

K. Maurer, Mannheim, Germany
G. Trendler, F. Hörrmann, H. Häfner

0-05-03

Basic symptoms and UHR criteria: Testing a sequential model of symptom development retrospectively

F. Schultze-Lutter, Cologne, Germany
S. Ruhrmann, V. Veith, J. Klosterkötter

0-05-04

Identifying children at risk for schizophrenia: A necessary step to new prospective investigations aiming to clarify aetiological processes

S. Hodgins, London, United Kingdom
K. Laurens

0-05-05

Coping in putatively prodromal persons and healthy controls

J. Paruch, Cologne, Germany
S. Ruhrmann, F. Schultze-Lutter, H. Picker,
H. Graf von Reventlow, M. Neumann, V. Veith,
A. Bechdorf, J. Klosterkötter

0-05-06

Premorbid adjustment and clinical symptoms in patients with first episode psychosis

R. Pollice, L'Aquila, Italy
E. di Giovambattista, A. di Pucchio, M. Mazza,
D. Ussorio, A. Tomassini, R. Roncone, M. Casacchia

INFORMATION FAIR

An information fair on schizophrenia for persons concerned, relatives and interested parties will be organised by the conference organisers following the 1st European Conference on Schizophrenia Research. Lectures, consultation hours as well as exhibition booths will be offered to provide information and awareness training in the field of schizophrenia.

The information fair is scheduled for **Saturday, 29 September 2007 from 10.00 am until 5.00 pm**. All sessions will be held in German and are available free of charge to the public at the Haus der Ärzteschaft.

LIST OF EXHIBITORS/FLOOR PLAN

Acknowledgments

The organisers of the 1st European Conference on Schizophrenia Research gratefully acknowledge the support of the following institutions and companies (as of September 2007)

BMBF



Janssen Cilag GmbH



Lilly Deutschland GmbH



Exhibitors

AstraZeneca GmbH

Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde

Janssen Cilag GmbH

Kompetenznetz Schizophrenie (KNS)

Lilly Deutschland GmbH


Open the Doors e.V.

Otsuka Pharma GmbH

Pfizer Pharma GmbH

Conference Rooms and Exhibiton Area

Haus der Ärzteschaft, Düsseldorf



A

Abdel-Hamid, M.24
 Agelink, M. W.25
 Ajdacic-Gross, V.22
 Alda Diez, J. A.23
 Altmann, C.17
 Andersch, N.18
 Angst, J. 22
 Anilkumar, A.14
 Arab, R.18
 Arends, M.25
 Arfeller, C.26
 Arolt, V.25
 Arshi, S.18
 Assion, H.-J.26
 Award, G.22

B

Bahn, S.13
 Bahrami, F.15
 Banos Yeste, I.23
 Barajas Velez, A.23
 Barkhatova, A.25
 Bauer, M.24
 Baumann, A.18
 Bäuml, J.20
 Bechdorf, A.13, 14, 23, 26, 27
 Bengtsson, F.22
 Berger, H.15, 22
 Berning, J.26
 Bernstein, H.-G.16
 Birchwood, M.23
 Bittner, R.16, 17
 Bogerts, B.16
 Bohner, G.16
 Bosch, P.18
 Boyko, Y.18
 Brand, A.20
 Brand, M.15
 Braun, C.26
 Braus, D.F.14
 Bremme, P.26
 Brinkmeyer, J.26
 Brockhaus-Dumke, A.17, 26
 Broome, M. R.15
 Brown, R.16
 Browne, S.22
 Brüne, M.16
 Bushe, C.24
 Büttner, S.22

C

Cahn, W.13
 Camen, D.16
 Casacchia, M.27
 Caton, S.18
 Chatton, A.24
 Chimorghiacis, A.16
 Clarke, M.22
 Coman, H.22
 Cordes, J.24, 25
 Cosman, D.22

Craciun, I.17
 Crumlish, N.22

D

d' Agostino, A.25
 Daskalakis, Z.J.26
 Dazzan, P.15
 Dembler, T.24
 Dettling, J.M.16
 Devitt, P.24
 Dingemans, P.23
 Dinges, M.24
 Dollase, D.21
 Dolz Abadia, M.23
 Drees, A.15
 Dreher, J.17
 Dreher-Rudolf, M.M.19
 Duno, R.25
 Durst, R.14, 25

E

Eggers, C.20
 Elsabagh, S.14
 Emsley, R.18, 19
 Engeland, H. van14
 Esslinger, C.17
 Ettinger, U.20

F

Fahy, K.21
 Falkai, P.13, 16, 17, 21, 26
 Fargas Villanueva, A.23
 Fathian, A.22
 Fehsel, K.24
 Ferrea, S.17
 Fischer-Barnicol, D.22
 Fleischhacker, W.15, 19
 Fleiter, J.15
 Fleming McCrossan, M.24
 Foroughmand, A. M.16
 Fresard, E.24
 Freyberger, H.J.26
 Froböse, T.20
 Frommann, I.14, 17, 26
 Frommann, N.15, 19

G

Gaebel, W.12, 14, 18, 19, 21, 23, 25, 26
 Gallhofer, B.17, 20
 Gallinat, J.16, 17, 22, 24, 25
 Gamma, A.22
 Gent, E. van24
 Gervin, M.22
 Ghamarigivi, H.18
 Giovambattista, E. di27
 Glaehdari, H.22
 Glenthøj, B.13
 Goebel, R.16, 17
 Govorin, N.25
 Gruber, O.14, 17
 Gsottschneider, A.20
 Gudlowski, Y.16

INDEX OF AUTHORS AND CHAIRPERSONS

H		
Habel, U.	14	Kotrotsios, G.
Hack, E.	26	Kraemer, S.
Haenschel, C.	14, 16, 17	Krebs, M.
Häfner, H.	13, 14, 15, 23, 26, 27	Kremlacek, J.
Haggard, P.	25	Kuba, M.
Häke, I.	17	Kukulska, D.
Haley, C.	24	Kumari, V.
Halfmann, S.	19	Kunz, D.
Haro Abad, J. M.	23	
Härtling, F.	16, 17	L
Hauner, H.	24	Lächler, M.
Hausdorf, G.	12	Lamprecht, A.
Hauser, M.	25	Landolt, K.
Heinimaa, M.	23	Langohr, J.K.
Heinz, A.	16, 22, 24, 25	Langquillon, S.
Hemmerle, M.	20	Larach-Walters, V.
Henn, F. A.	14	Larkin, C.
Henning, U.	17	Laurens, K.
Hochrein, A.	26	Lautenschläger, M.
Hodgins, S.	27	Lebedeva, I.
Holdenrieder, S.	16	Leopold, K.
Hörmann, F.	15, 27	Levy, P.
Höschl, C.	12, 21	Leweke, M.
Huttunen, J.	23	Lewis, S.
		Libiger, J.
J		Liensdorf, C.
Jahn, T.	20	Limosani, I.
Janssen, B.	22	Linden, D.
Jarema, M.	25	Lindner, M.
Jimeno Bulnes, N.	25	Linszen, D.
Joukamaa, M.	18	Lis, S.
Juckel, G.	16, 23, 24	Lopez-Garcia, P.
		Lublin, H.
K		Luckhaus, C.
Kadovic, D.	17	Luutonen, S.
Kahnt, T.	24	
Kaiser, W.	18	M
Kalafi, Y.	18	Macrea, R.
Kaleda, V.	25	Mager, M.
Kamali, M.	22	Maier, W.
Kassaiean, N.	15	Mamchur, V.
Kasyan, L.	24	Manea, M.
Kaufmann, C.	16	Manzone, M. L.
Keefe, R.	12	Marder, S.
Kellermann, T.	14	Marinescu, D. G. Constantin
Khazaal, Y.	24	Marshall, M.
Khomenko, Y.	17	Matuschek, E.
Kienast, T.	24	Maurer, K.
Kinsella, A.	22	Mazza, M.
Kircher, T.	14	McGuire, P.
Kirsch, P.	17, 20	McNamara, D.
Klimke, A.	24	McTigue, O.
Klingberg, S.	19	Meisenzahl, E.
Klingebl, R.	16	Meyer-Lindenberg, A.
Klosterkötter, J.	13, 14, 21, 23, 26, 27	Miclutia, I. V.
Knöchel, C.	17	Mier, D.
Knutson, B.	24	Mittrach, M.
Koelkebeck, K.	25	Mobascher, A.
Koivisto, A.-M.	18	Moeller, B.
Körtner, K.	16	Mohamad Shariati, S.A.
Koslowski, M.	24	Molavi, P.
Kotlicka-Antczak, M.	26	Molero, P.
		Möller, H.-J.

Moore, J.25
 Müller, D.22
 Müller, D.R.19
 Müller, N.16
 Müller-Spahn, F. 12, 18

N

Nemes, B.22
 Neumann, M.15, 23, 27
 Nica, S.22
 Niedersteberg, A.14
 Noort, M. van den18
 Nooten, F. van16
 Nordentoft, M. 13, 19, 21

O

O' Callaghan, E.22
 Oades, R.D.20
 Ochoa Güerre, S.23
 Oertel, V.17
 Ohrmann, P.25
 Oja, H.18
 Omelchenko, M.25
 Ortuno, F.22
 Özgürdal, S.16

P

Palchikov, V.24
 Panina, A.25
 Papageorgiou, K.15
 Parnowska, D.25
 Paruch, J. 23, 27
 Patino-Garcia, A.22
 Patterson, P.23
 Pedersen, A.25
 Peltzer, M.15
 Petrovsky, N.17
 Pfeffer, K. D.12
 Piaszek, A.19
 Picker, H. 15, 23, 27
 Pitschel-Walz, G.20
 Plewnia, C.26
 Pohl, C.20
 Pollice, R.27
 Pombo, S.18
 Popescu, C.A.17
 Pousa, E.25
 Premkumar, P.14
 Prokudin, V.18
 Pucchio, A. di27
 Puls, I.16

R

Rabe-Jablonska, J.26
 Radut, C.16
 Rantanen, H.18
 Rapp, A.14
 Raskin, S. 14, 25
 Rausch, F.15
 Reventlow, H. Graf von23, 27
 Rezaei Ghalechi, E.18
 Riedel, M.16
 Riesbeck, M.23

Rijnders, C.16
 Rilk, A.26
 Roder, V.19
 Rodionov, V. 14, 25
 Rodriguez, E.14
 Roebroeck, A.17
 Rogue, P. J.22
 Roncone, R.27
 Ronshausen, S.17
 Röpcke, B.20
 Rosenbaum, B.19
 Rössler, W.12, 18, 22
 Rotarska-Jagiela, A. 16, 17
 Roux, F.14
 Ruhrmann, S. 13, 14, 15, 17, 23, 26, 27
 Rujescu, D.22

S

Saeedlou, S.18
 Salokangas, R. K. R. 13, 14, 18, 23
 Sanchez, V.15
 Sanchez Fernandez, B.23
 Sauer, C.17
 Sauer, H.14
 Scarone, S.25
 Schaefer, M.15
 Schäfer, M.17
 Schelde, T.22
 Schimmelmann, B.G.26
 Schlagenhaut, F. 16, 22, 24
 Schloegelhofer, M.15
 Schlösser, R.14
 Schmack, K.24
 Schmidbauer, W.15
 Schmidt, F.16
 Schmitt, A. 14, 16
 Schneider, F.14
 Schneider, M.17
 Schothorst, P.14
 Schubert, F.17
 Schultze-Lutter, F. 14, 15, 23, 27
 Schulze-Rauschenbach, S.17
 Schwarz, M. J.16
 Seifert, F.17
 Shah, N.J.14
 Shariati, S. A. Mohamad22
 Shlafman, M. 14, 25
 Siegmund, A.25
 Simon, A.21
 Singer, W.14, 16, 17
 Skachko, T.24
 Skachko-Volkova, T.17
 Snyder, J.S.26
 Soekadar, S. R.26
 Sprong, M.14
 Steinbring, A.15
 Steyskal, C.16
 Stöcker, T.14
 Streit, M.19
 Stulz, N.22
 Sushko, V.16
 Suslow, T.25
 Swaab, H.14

T

Tarabara, I.	24
Teitelbaum, A.	14, 25
Thienel, R.	14
Thünker, J.	24, 25
Tischinger, M.	16
Tiugan, A.	16
Tomassini, A.	27
Torre, E.	18
Trendler, G.	15, 27

U

Udristoiu, T.	16
Ufer, S.	14
Uhlhaas, P.	14
Urban, A.	14
Usall Rodie, J.	23
Ussorio, D.	27

V

Valmaggia, L.R.	15
Vanelli, I.	18
Vargas, M. L.	25
Vauth, R.	19
Veith, V.	14, 23, 27
Ven, V. van de	17
Villalta Gil, V.	23
Vita, A.	13, 14
Voss, M.	25

W

Waddington, J.L.	22
Wagner, M.	13, 14, 17, 23, 24, 26
Weiler, C.	17
Weiss-Motz, F.	17
Whitty, P.	22
Wiedl, K. H.	25
Witthaus, H.	16
Wobrock, T.	17, 25
Wölwer, W.	15, 19, 21, 25, 26
Wrase, J.	16, 22, 24
Wunderink, L.	19, 21
Wüstenberg, T.	24
Wykes, T.	21

Z

Zamani, A.	15
Zäske, H.	18
Zilles, K.	14
Zlenko, H.	17, 24
Zullino, D.	24
Zygodnik, K.	17

Pathways to Integrative Care



ASSOCIATION OF EUROPEAN PSYCHIATRISTS
**16th EUROPEAN CONGRESS
OF PSYCHIATRY**
Nice, France April 5-9, 2008



**Deadline date for Abstracts:
November 1, 2007**

**CME
Accreditation
is being
applied for**

www.kenes.com/aep



For further information please contact
Congress Organizers

KENES International
AGENCY FOR YOUR ORGANIZATION
MEDICAL CONGRESS ORGANIZERS AND
REGISTRATION MANAGEMENT SERVICES

1-3 Rue de Chantepoulet, PO Box 1726, CH-1211 Geneva 1, Switzerland
Tel : +41 22 908 0488, Fax : +41 22 732 2850, E-mail: aep@kenes.com

Schizophrenia Bulletin

www.schizophreniabulletin.oxfordjournals.org

Schizophrenia Bulletin – a leading academic journal,
keeping clinicians informed of the latest
developments in schizophrenia research

AUTHOR BENEFITS

- Online submission
- Manuscript tracking through the review process
- Article usage and citations information
- Advanced Access – rapid online publication, and immediately citeable

READER BENEFITS

- **FREE** contents alerting
- **FREE** Sample issue
- **FREE** All content over 12 months old
- Enhanced searching

OXFORD OPEN

An optional open access model, giving authors the opportunity to publish and allow online access to their content for free immediately upon publication



SUBSCRIBE

Discounted subscription rates for ICOSR delegates.
Find all subscription information at the website:
www.schizophreniabulletin.oxfordjournals.org

